AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01638923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV/DNG (Qlaira, Natazia, BAY86-5027)
Description: 2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placebo. A blister card consists of 28 pills, taken orally once a day for 7 cycles of 28 days each.
Study NCT01638923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo to be taken orally daily for 7 cycles of 28 days each.
Study NCT03331120 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ambulatory mirror image functional re-training through wearing 3D adjustable cervicothoracic Posture Corrective Orthotic(CTPCO)
Description: Ambulatory a mirror image functional re-training This way of functional training will deliver via the use of adjustable cervicothoracic orthosis with the patient walking at approximately 2-3 miles per hour on a standard, motorized treadmill. The brace will reverse the abnormal posture according to the 3D posture analysis data. To facilitate tissue remodeling by reverse posture training, this called mirror image exercise.then the ambulatory exercises by using treadmill will be performed while the patient's mirror image posture will be held by the adjustable orthosis, ambulatory exercises for 20 minutes by using treadmill Based on Harrison et al and Hawes et al., approach, this program will be repeated 3 Times /week for 10 weeks.
Study NCT03331120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ambulatory mirror image functional re-training through wearing 3D adjustable cervicothoracic Posture Corrective Orthotic(CTPCO)
Description: Ambulatory a mirror image functional re-training This way of functional training will deliver via the use of adjustable cervicothoracic orthosis with the patient walking at approximately 2-3 miles per hour on a standard, motorized treadmill. The brace will reverse the abnormal posture according to the 3D posture analysis data. To facilitate tissue remodeling by reverse posture training, this called mirror image exercise.then the ambulatory exercises by using treadmill will be performed while the patient's mirror image posture will be held by the adjustable orthosis, ambulatory exercises for 20 minutes by using treadmill Based on Harrison et al and Hawes et al., approach, this program will be repeated 3 Times /week for 10 weeks.
Study NCT02672046 — intervention group
Intervention type: OTHER
Intervention: Assessment at the Clinic of Sports Injuries
Description: Assessment at the Clinic of Sports Injuries as well as a new algorithm (using patient-reported symptoms will be applied
Study NCT01204190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gestodene/EE Patch (BAY86-5016)
Description: 0.55 mg ethinyl estradiol (EE) + 2.1 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
Study NCT01204190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gestodene/EE Patch (BAY86-5016)
Description: 0.35 mg ethinyl estradiol (EE) + 0.67 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
Study NCT01204190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gestodene/EE Patch (BAY86-5016)
Description: 0.275 mg ethiny estradiol (EE) + 1.05 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
Study NCT02683538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Separable cluster electrode (Octopus®)
Description: Patients undergo RFA under ultrasound guidance, and separable cluster electrodes are used for RFA in monopolar switching mode, using multiple overlapping technique to create larger ablative zones.
Study NCT03798691 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: Biological: SHINGRIX~SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 18 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized glycoprotein e (ge) antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later.
Study NCT00754130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941
Description: MK-0941 5 mg tablets q.a.c.; 10 mg tablets q.a.c.; 20 mg tablets q.a.c.; or 40 mg tablets q.a.c. Treatment period is 5 days.
Study NCT00731276 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: irinotecan hydrochloride
Study NCT00731276 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pharmacogenomic studies
Study NCT00731276 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pharmacological study
Study NCT01107912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prasugrel
Description: administered orally, daily for 12 days
Study NCT01107912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel
Description: administered orally, daily for 12 days
Study NCT01734512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus tablet will be taken daily by mouth with water. All patients will be given a dose of 5 mg/m2/dose daily.
Study NCT01107912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Administered orally, daily for 12 days
Study NCT00904501 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bone marrow harvest
Description: Implantation of placebo
Study NCT00904501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow harvest
Description: Implantation of bone marrow - mononuclear cells
Study NCT01870700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lactobacillus reuteri
Description: Lactobacillus reuteri (DSM 17938) was administered in the dose of 108 colony-forming units (CFU) in tablets of a commercially available preparation (Reuflor, Italchimici, Pomezia; BioGaia AB, Stockholm, Sweden), 30 minutes after feeding, twice per day for 4 weeks
Study NCT01547273 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone graft inside socket only
Description: bone graft inside socket only
Study NCT01547273 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone graft inside and outside socket
Description: bone graft inside and outside socket
Study NCT01547273 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no bone graft
Description: no bone graft
Study NCT01089985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous serum eyedrops
Description: 3 times a day for the duration of the study
Study NCT02015468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early mobilization
Description: Early weightbearing and physiotherapy
Study NCT02015468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Late mobilization
Description: Late mobilization, none-weightbearing and home exercises
Study NCT03319901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is an inhibitor of Bcl-2. Bcl-2 is critical for keeping cancer cells alive.~By inhibiting Bcl-2, venetoclax promotes cancer cell death.
Study NCT03319901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Chemotherapy
Description: Standard treatment of chemotherapy is administered
Study NCT03218631 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxandrin
Description: The primary outcome for this study will be measurements of the pharmacokinetics of a single dose of oxandrolone 0.1 mg/kg both in tablet form and in the MCT oil preparation. Blood samples for pharmacokinetics will be drawn at 9 timepoints.~Safety will be assessed by recording adverse events and assessment of hepatic function at baseline and one week following oxandrolone dosing.
Study NCT00422773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Dose level Infusion time (h) Dose level unit 1 2 3 4 Cetuximab 2.0 mg/m² 500 500 500 500 Irinotecan, before oxaliplatin 1.0 mg/m² 95 125 165 180 Oxaliplatin, with folinic acid 2.0 mg/m² 85 85 85 85 Folinic acid, with folinic acid 2.0 mg/m² 400 400 400 400 5-FU Infusion 46.0 mg/m² 3200 3200 3200 3200
Study NCT01003548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMART dynamic system of embryo culture
Description: Embryos will be cultured in a dynamic system of microfluidics.
Study NCT01003548 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Static culture
Description: Embryos cultured in 40 microliters microdrops of G-IVF plus series V
Study NCT00646256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COGPACK training, psychoeducation
Description: Bifocal psychoeducation group program (Munich Psychoses Information Program - PIP) with preceding computerbased cognitive training program (COGPACK)
Study NCT00612079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertindole
Description: oral 3 x 4mg
Study NCT00612079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 x 4mg Placebo
Study NCT02606682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPT200-11
Description: Single doses of NPT200-11capsules, orally administered
Study NCT02606682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single doses of microcrystalline cellulose capsules, orally administered
Study NCT00612794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide once weekly
Description: subcutaneous injection, once weekly
Study NCT00612794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection, once weekly
Study NCT00685022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI
Description: 1. Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)~2. Arm #A~3. Xopenex HFA MDI, albuterol HFA MDI
Study NCT00685022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racemic Albuterol followed by levalbuterol HFA MDI
Description: 1. Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)~2. Arm #B~3. albuterol HFA MDI, Xopenex HFA MDI
Study NCT02243059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadofosveset trisodium (Ablavar™ )
Study NCT02243059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT01831531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 40 mg (BSA ≤ 1.6 m2) or 50 mg (BSA >1.6 m2) p.o bid d1-28
Study NCT01831531 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
Study NCT05889026 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave therapy
Description: Stimulation was given to the brachial muscle, 1000 times, 4Hz, and energy flux density was 0.030mJ/mm2.
Study NCT01870700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a supplementation with placebo was administered in tablets of a commercially available preparation 30 minutes after feeding, twice per day for 4 weeks
Study NCT05889026 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Botulinum toxin treatment
Description: The toxin dose was established for each patient: it ranged between 80 unit and 300 unit.
Study NCT05889026 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin treatment
Description: The toxin dose was established for each patient: it ranged between 80 unit and 300 unit.
Study NCT04334330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant
Description: ER/PR positive, HER2-positive breast cancer patients with brain metastatic lesions receive palbociclib PO daily on days 1-21, combined with trastuzumab IV every three weeks, pyrotinib PO daily and fulvestrant IM every 4 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Study NCT03975088 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sub-macular injection of Ranibizumab
Description: In this study, authors describe a new surgical technique for the treatment of refractory non tractional DME. The technique consists of vitrectomy with ILM peeling with subretinal injection of Ranibizumab.
Study NCT02733601 — intervention group
Intervention type: OTHER
Intervention: NIS (Non Interventional Study) observational study
Description: NIS observational study : Epidemiologic registry
Study NCT02917928 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: carnosine
Description: Each participant will be given a daily oral dose 2 g of carnosine (4 tablets of 500mg each) for 14 weeks
Study NCT02917928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will be given a daily oral dose 2 g of placebo (4 tablets of 500mg each) for 14 weeks
Study NCT01268137 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Deep Brain Stimulation
Description: Surgical electrode implantation in the white matter adjacent to the Cg25 region and implantation of the DBS pulse generating device
Study NCT01268137 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: Surgical electrode implantation in the white matter adjacent to the Cg25 region and implantation of the DBS pulse generating device
Study NCT02503566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography
Description: Optical coherence tomography performed during regular coronary angiography
Study NCT02523274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Dietary compound commonly found in grapes and red wine. Will be given in 250 mg/day and 1000 mg/day dosages
Study NCT02523274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vegetable-based cellulose
Study NCT02523274 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Multi-modal exercise regimen, 3 days/week
Study NCT02523274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Multi-modal exercise regimen, 3 days/week
Study NCT01884116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID patch
Study NCT01884116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID patch + transcutaneous electric nerve stimulation
Description: The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
Study NCT01884116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID patch + heating pad
Description: The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
Study NCT01884116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID patch + topical capsaicin
Description: The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
Study NCT06267677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein liquid formula
Description: liquid and high amount of protein
Study NCT02316678 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention
Study NCT02757131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambulation
Description: Patients randomized to the intervention group will be asked to participate in the ambulation protocol outlined by the PT staff 3 times daily under the supervision of the dedicated ambulator PCNA. This protocol will involve four exercise levels (mobilization, standing, walking, stairs) that may be implemented depending on the current physical capacity of the patient. The cohort of patients randomized to ambulator protocol will also receive the usual care by primary nursing.~In an effort to best characterize mobility in these patients, the team will collect Braden Scale Activity data from the electronic health record, and provide each patient a mobility tracking device to directly record daily steps taken while the patient is in the hospital. Daily step counts will be collected on a weekly basis from each device. The Braden Scale is entered by nursing on each patient at least daily and measures current activity level on a 4-point scale.
Study NCT02952079 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blephex
Description: Lid margin exfoliation
Study NCT02952079 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MiboFlo
Description: Lid warming treatment
Study NCT01903655 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: telomere length
Study NCT02584049 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathy
Description: 3 sessions of osteopathy during 60 minutes each
Study NCT02584049 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham osteopathy
Description: 3 sessions of sham osteopathy during 60 minutes each
Study NCT01115439 — intervention group
Intervention type: DRUG
Intervention: artesunate plus sulfadoxine-pyrimethamine (AS+SP)
Description: artesunate plus sulfadoxine-pyrimethamine (AS+SP)
Study NCT04558346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin (OXE-103)
Description: 40ug/kg twice daily by self-injection
Study NCT04558346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40ug/kg twice daily by self-injection
Study NCT03223558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: timing of initiation of cardiac rehabilitation
Description: earlier timing of cardiac rehabilitation
Study NCT03223558 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: timing of initiation of cardiac rehabilitation
Description: earlier timing of cardiac rehabilitation
Study NCT01778465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low salicylate diet
Description: Participants followed a 7 days period under a Low salicylate diet
Study NCT01778465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal Diet
Description: Participants followed a 7 days period under a Normal Diet
Study NCT02266628 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV-F Vaccine
Study NCT02266628 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Study NCT01527201 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic debridement
Description: Surgeon will debride, or remove, worn out cartilage.
Study NCT00709384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic surgical lesion
Description: A prophylactic peroperative linear lesions connecting the tricuspid annulus with a right atriotomy (surgical dissection plus cryoablation) and the atriotomy with the inferior caval vein (cryoablation alone).
Study NCT03351023 — intervention group
Intervention type: OTHER
Intervention: no intervention-this was an observational study
Study NCT01263275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS (Eldith DC-Stimulator (CE certified))
Description: Each tDCS session lasting continuously for 20 minutes at 2 mA
Study NCT02177058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INTERACT Quality improvement program
Description: INTERACT training and implementation between APR 2013 and MAR 2014
Study NCT02177058 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quarterly surveys/data reporting
Description: The nursing homes are asked to complete quarterly surveys between APR 2013 to MAR 2014
Study NCT02656615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label).
Study NCT02551926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile text messages
Study NCT02551926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual community
Study NCT01864525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octanoic acid
Study NCT02551926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brochures
Study NCT02551926 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Study NCT02551926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile phone